A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
Nurix Therapeutics, Inc.
Nurix Therapeutics, Inc.
Eli Lilly and Company
Ascentage Pharma Group Inc.
Newave Pharmaceutical Inc
Schrödinger, Inc.
AbbVie
Carna Biosciences, Inc.
Mayo Clinic
City of Hope Medical Center
Accutar Biotechnology Inc
Boryung Pharmaceutical Co., Ltd
Memorial Sloan Kettering Cancer Center
Stanford University
Nurix Therapeutics, Inc.
Bio-Path Holdings, Inc.
Calibr, a division of Scripps Research
Nkarta, Inc.
Xencor, Inc.
Calibr, a division of Scripps Research
Stanford University
VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Stanford University
Dartmouth-Hitchcock Medical Center
Canadian Cancer Trials Group
Hutchmed
Brown University
AbbVie
Karyopharm Therapeutics Inc
TG Therapeutics, Inc.
Qilu Puget Sound Biotherapeutics (dba Sound Biologics)
ADC Therapeutics S.A.
Fred Hutchinson Cancer Center
University of Michigan Rogel Cancer Center
Barbara Ann Karmanos Cancer Institute
Barbara Ann Karmanos Cancer Institute
M.D. Anderson Cancer Center
Dana-Farber Cancer Institute
University of Wisconsin, Madison
National Institutes of Health Clinical Center (CC)
Celgene
Alliance for Clinical Trials in Oncology
Swiss Cancer Institute
Wake Forest University Health Sciences
Ohio State University Comprehensive Cancer Center
National Cancer Institute (NCI)
Cancer Research UK
Masonic Cancer Center, University of Minnesota
National Cancer Institute (NCI)
California Cancer Consortium
Janssen Research & Development, LLC